Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmu...
Q1 2026
May 7, 2026
FY 2025
Mar 10, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 7, 2025